Correction to “Weight Loss and Dysgeusia in Relapsed/Refractory Multiple Myeloma Patients Treated With Talquetamab”

EJHaem Pub Date : 2025-05-19 DOI:10.1002/jha2.70052

引用次数: 0

Abstract

Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S, Zangari M, et al. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. eJHaem. 2024;5:789–792. doi: 10.1002/jha2.971

Carolina Schinke has mistakenly not declared her Conflict of Interest and would like to add a sentence stating “CS has participated in Advisory Board Meetings of Janssen, Pfizer and Arcellx”.

We apologize for this error.

查看原文本刊更多论文

对“复发/难治性多发性骨髓瘤患者接受Talquetamab治疗后体重减轻和认知障碍”的更正

Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S， Zangari M等。talquetamab治疗复发/难治性多发性骨髓瘤患者的体重减轻和认知障碍eJHaem。2024; 5:789 - 792。carolina Schinke错误地没有声明她的利益冲突，并希望添加一句“CS参加了Janssen， Pfizer和Arcellx的顾问委员会会议”。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量